CASI vs. THTX, VYNE, ACXP, IPA, VIRX, FBIO, NRXP, DARE, APRE, and XLO
Should you be buying CASI Pharmaceuticals stock or one of its competitors? The main competitors of CASI Pharmaceuticals include Theratechnologies (THTX), VYNE Therapeutics (VYNE), Acurx Pharmaceuticals (ACXP), ImmunoPrecise Antibodies (IPA), Viracta Therapeutics (VIRX), Fortress Biotech (FBIO), NRx Pharmaceuticals (NRXP), Daré Bioscience (DARE), Aprea Therapeutics (APRE), and Xilio Therapeutics (XLO). These companies are all part of the "pharmaceutical preparations" industry.
CASI Pharmaceuticals (NASDAQ:CASI) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.
CASI Pharmaceuticals presently has a consensus target price of $12.00, indicating a potential upside of 402.09%. Given CASI Pharmaceuticals' higher possible upside, research analysts plainly believe CASI Pharmaceuticals is more favorable than Theratechnologies.
CASI Pharmaceuticals received 170 more outperform votes than Theratechnologies when rated by MarketBeat users. However, 52.73% of users gave Theratechnologies an outperform vote while only 51.69% of users gave CASI Pharmaceuticals an outperform vote.
22.2% of CASI Pharmaceuticals shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, CASI Pharmaceuticals had 2 more articles in the media than Theratechnologies. MarketBeat recorded 3 mentions for CASI Pharmaceuticals and 1 mentions for Theratechnologies. CASI Pharmaceuticals' average media sentiment score of 0.82 beat Theratechnologies' score of 0.00 indicating that CASI Pharmaceuticals is being referred to more favorably in the media.
Theratechnologies has a net margin of -23.04% compared to CASI Pharmaceuticals' net margin of -79.30%. Theratechnologies' return on equity of 0.00% beat CASI Pharmaceuticals' return on equity.
Theratechnologies has higher revenue and earnings than CASI Pharmaceuticals. Theratechnologies is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
CASI Pharmaceuticals beats Theratechnologies on 8 of the 15 factors compared between the two stocks.
Get CASI Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CASI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CASI Pharmaceuticals Competitors List
Related Companies and Tools
